# A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

> **NCT05247489** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 55 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Ruxolitinib 1.5% cream
- **DEVICE:** NB-UVB phototherapy

## Key facts

- **NCT ID:** NCT05247489
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-05
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247489, "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05247489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*